Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD; CentoCor Ortho Biotech Products L.P., Raritan, NJ, USA). over single-agent PLD in 672 patients with relapsed ovarian cancer, particularly in the partially platinum-sensit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaye, S. B., Colombo, N., Monk, B. J., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Vergote, I., Lebedinsky, C., Parekh, T., Santabárbara, P., Park, Y. C., Nieto, A., Poveda, A.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003617/
https://www.ncbi.nlm.nih.gov/pubmed/20643863
http://dx.doi.org/10.1093/annonc/mdq353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003617/
https://www.ncbi.nlm.nih.gov/pubmed/20643863
http://dx.doi.org/10.1093/annonc/mdq353

Ejemplares similares